Statement of Standalone Un-Audited Financial Results for the Quarter and Nine Months ended December 31, 2021

(Rs. In Lakhs, unless otherwise stated) Nine Months ended Quarter ended Year ended Sr. No. **Particulars** 31-12-2021 31-12-2020 31-03-2021 31-12-2021 30-09-2021 31-12-2020 (Audited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Income (a) Revenue from operations 3267.32 3693.30 813.66 2229.70 1237.16 1192.89 (b) Other Income 0.20 0.31 0.47 9.26 Total Income 3267.64 2230.17 3702.56 813.66 1237.26 1193.08 Expenses (a) Cost of Materials Consumed 1581.21 1079.15 391.76 479.77 375-79 1139.36 (b) Purchases of Stock-in-Trade (c) Changes in Inventories of Finished Goods, 147.86 42.02 (288.37)235.61 (849.94)(544.79)Work-in-Progress & Stock-in-Trade (d) Employee Benefits Expense 817.42 701.80 997.98 298.75 238.87 273.44 (e) Finance Costs 46.02 201.68 44.98 136.95 115.09 45.52 (f) Depreciation and Amortisation Expense 125.94 155.08 38.52 40.53 43.79 115.59 (g) Other Expenses 304.88 252.81 345.85 743.78 931.30 1158.41 **Total Expenses** 1202.48 1159.39 760.91 3188.71 2103.34 3549-57 Profit before Tax (1-2) 126.83 33.69 78.92 152.99 52.74 34.77 Tax Expense (a) Current Tax 18.21 19.87 54.00 31.92 11.30 8.57 (b) Deferred tax 2.81 **Total Tax Expense** 56.81 8.57 18.21 19.87 31.92 11.30 Profit after Tax for the period (3-4) 23.48 25.12 59.06 96.18 34-53 94.91 5 Other Comprehensive Income A. (I) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B. (I) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to Total Comprehensive Income for the period (5 + 6) (comprising 7 Profit for the period after tax and other comprehensive Income 23.48 25.12 34.53 59.06 94-91 96.18 after tax) **Details of Equity Share Capital** Paid up Equity capital (Face Value of Rs.10/- each) 364.83 364.83 364.83 364.83 364.83 364.83 Face value of Equity Share Capital 10.00 10.00 10.00 10.00 10.00 10.00 Earnings Per Equity Share (Face Value of Rs.10/- each) (a) Basic (Rs.) 0.64 0.69 0.95 1.62 2.60 2.64 (b) Diluted (Rs.) 0.64 0.69 0.95 1.62 2.60 2.64

Notes:

- 1). The above unaudited financial results of Centenial Surgical Suture Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on February 10, 2022. The Statutory Auditors of the Company have carried out a limited review on the financial results and have expressed an unmodified conclusion thereon.
- 2). The Company has one reportable business segment "Medical Devices".
- 3). The unaudited results for the Quarter and Nine months ended December 31, 2021 are available on the website of BSE Ltd. at www.bseindia.com and on Company's website at www.centenialindia.com.
- 4). These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 5). COVID-19 is the infectious disease caused by coronavirus, SARS-COV-2. In March 2020, the WHO declared COVID-19 a pandemic. The Company has adopted measures to curb the spread of infection in order to protect the health of the employees and ensure business continuity with minimal disruption. In assessing the recoverability of receivables and other financial assets, the Company has considered internal and external information upto the date of approval of these financial results. The impact of the global health pandemic may be different from that of estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material manges to future economic conditions.
- 6). The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.

MURBAD S

d on behalf of the Board of Directors of ENTENIAL SURGICAL SUTURE LIPD.

Vijay MAJREKAR Managing Director ~ DIN: 00804808

Place: Mumbai, Maharashtra Date: February 10, 2022